Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1232 participants.

Also called NCT06742216

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,232 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06742216
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06742216. Randomized; quadruple masking; primary purpose treatment. Start 2020-11-03 (actual); primary completion 2023-08-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study
Condition
Acute Ischemic Stroke
Intervention (Drug)
Monosialoganglioside
Intervention (Drug)
Placebo
Lead sponsor
Qilu Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06742216
Content hash
376f8be21d17f767b4857d1e00396c9afe160bb0a8d9409e388390bfcd6718ce